Biochemical and behavioral effects of boldine and glaucine on dopamine systems

Pharmacology Biochemistry and Behavior

Volumn 62, Issue 1, 1999, Pages 7-13

  Asencio, M ^a,b   Delaquerriere B ^b   Cassels, B K ^a   Speisky, H ^a   Comoy, E ^c   Protais, P ^b  

^a UNIVERSITY OF CHILE   (Chile)

^b Lab de Pharmachimie et Biopharm   (France)

^c UFR de Med Pharmacie de Rouen   (France)

Author keywords

Affinity; Boldine; Climbing; D1 D2 antagonists; Dopamine metabolism; Glaucine; Grooming; Neuroleptic like; Penile erection; Sniffing; Yawning

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; APORPHINE DERIVATIVE; BOLDINE; CHLORPROMAZINE; GLAUCINE; RACLOPRIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; BRAIN; CLIMBING; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG RECEPTOR BINDING; GROOMING; IN VITRO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PENIS ERECTION; PRIORITY JOURNAL; RAT; SNIFFING; YAWNING;

ANIMALS; ANTIOXIDANTS; APORPHINES; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; LIGANDS; MALE; MICE; PENILE ERECTION; RATS; RATS, WISTAR; YAWNING;

POROMITRA OSCITANS;

EID: 0032930043     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00096-3     Document Type: Article

References (35)

1. 3H]-SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur. J. Pharmacol. 146:1988;113-120.
2. Asencio M., Cassels B.K., Manríquez V., Boys D. Structure of (S)-1,10-dimethoxy-2,9-dihydroxyaporphinium chloride (boldine hydrochloride). Acta Crystallogr. C. 52:1996;1581-1583.
3. Backhouse N., Delporte C., Guivernau M., Cassels B.K., Speisky H. Anti-inflammatory and antipyretic effects of boldine. Agents Actions. 42:1994;114-117.
4. Bannach R., Valenzuela A., Cassels B.K., Núñez-Vergara L.J., Speisky H. Cytoprotective and antioxidant effects of boldine on tert-butyl hydroperoxide-induced damage to isolated hepatocytes. Cell Biol. Toxicol. 12:1996;89-100.
5. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye-binding. Anal. Biochem. 72:1976;248-250.
6. Cassels B.K., Asencio M., Conget P., Speisky H., Videla L.A., Lissi E. Structure-antioxidative activity relationships in benzylisoquinoline alkaloids. Pharmacol. Res. 31:1995;103-107.
7. De Jong H., Baruk H. La catatonie expérimentale par la bulbocapnine. 1930;Masson et Cie, Paris.
8. Ernst A.M. Relation between the action of dopamine and apomorphine and their O-methylated derivatives upon the CNS. Psychopharmacologia. 7:1965;391-399.
9. Gao Y., Ram V.J., Campbell A., Kula N.S., Baldessarini R.J., Neumeyer J.L. Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2 and agonist receptor sites in rat brain. J. Med. Chem. 33:1990;39-44.
10. Gao Y., Baldessarini R.J., Kula N.S., Neumeyer J.L. Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. J. Med. Chem. 33:1990;1800-1805.
11. Gingrich J.A., Caron M.G. Recent advances in the molecular biology of dopamine receptors. Annu. Rev. Neurosci. 16:1993;299-321.
12. 3H]-SCH 23390 labelled D-1 dopamine receptors in rat striatum. Eur. J. Pharmacol. 121:1986;31-40.
13. Janssen P.A., Niemegeers C.J.C., Jagenau A.H.M. Apomorphine antagonism in rats. Arzneimittelforschung. 10:1960;1003-1005.
14. Kent R.S., De Lean A., Lefkowitz R.J. A quantitative analysis of beta-adrenergic receptor interactions. Resolution of high and low affinity states of the receptor by computer modeling of ligand binding data Mol. Pharmacol. 17:1980;14-23.
15. 3H]-raclopride. Biochem. Pharmacol. 34:1985;2251-2256.
16. Marçais H., Protais P., Costentin J., Schwartz J.C. A gradual score to evaluate the climbing behaviour elicited by apomorphine in mice. Psychopharmacology (Berlin). 56:1978;233-234.
17. Martres M.P., Costentin J., Baudry M., Marçais H., Protais P., Schwartz J.C. Long-term changes in the sensitivity of pre- and postsynaptic dopamine receptors in mouse striatum evidenced by behavioural and biochemical studies. Brain Res. 135:1977;319-330.
18. Martres M.P., Sokoloff P., Delandre M., Schwartz J.C., Protais P., Costentin J. Selection of dopamine antagonists discriminating various behavioral responses and radioligand binding sites. Naunyn Schmiedebergs Arch. Pharmacol. 325:1984;102-115.
19. Melis M.R., Argiolas A., Gessa G.L. Oxytocin-induced penile erections and yawning. Site of action in the brain Brain Res. 398:1986;259-265.
20. Molloy A.G., Waddington J.L. Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SK&F 38393 and its R- and S-enantiomers in the intact adult rat. Psychopharmacology (Berlin). 92:1987;164-171.
21. Neumeyer J.L. Synthesis and structure-activity relationships of aporphines as dopamine receptor agonists and antagonists. Phillipson J.D., Roberts M.F., Zenk M.H. The chemistry and biology of isoquinoline alkaloids. 1985;146-170 Springer, Berlin.
22. Protais P., Costentin J., Schwartz J.C. Climbing behavior induced by apomorphine in mice. A simple test for the study of dopamine receptors in striatum Psychopharmacology (Berlin). 50:1976;1-6.
23. Protais P., Dubuc I., Costentin J. Pharmacological characteristics of dopamine receptors involved in the dual effect of dopamine agonists on yawning behaviour in rats. Eur. J. Pharmacol. 94:1983;271-280.
24. 3H-raclopride binding sites. Experientia. 48:1992;27-30.
25. Seeman P. Brain dopamine receptors. Pharmacol. Rev. 32:1980;229-313.
26. Speisky H., Cassels B.K., Lissi E.A., Videla L.A. Antioxidant properties of the alkaloid boldine in systems undergoing lipid peroxidation and enzyme inactivation. Biochem. Pharmacol. 41:1991;1575-1582.
27. Speisky H., Cassels B.K., Sanhueza V., Nieto S., Valenzuela A., Núñez-Vergara L.J. Determination of boldine in plasma by HPLC. J. Chromatogr. Biomed. Appl. 612:1993;315-319.
28. Speisky H., Cassels B.K. Boldo and boldine. An emerging case of natural drug development Pharmacol. Res. 28:1994;1-12.
29. Trumpp-Kallmeyer S., Hoflack J., Bruinvels A., Hibert M. Modelling of G-protein-coupled receptors. Application to dopamine, adrenalin, serotonin, acetylcholine and mammalian opsin receptors. J. Med. Chem. 35:1992;3448-3462.
30. Tseng L.F., Walaszek E.J. Blockade of d-amphetamine-induced stereotyped behavior by bulbocapnine. Pharmacology. 7:1972;255-258.
31. Vasse M., Chagraoui A., Protais P. Climbing and stereotyped behaviours in mice require the stimulation of D-1 dopamine receptors. Eur. J. Pharmacol. 148:1988;221-229.
32. Vasse M., Protais P. Increased grooming behaviour is induced by apomorphine in mice treated with discriminant benzamide derivatives. Eur. J. Pharmacol. 156:1988;1-11.
33. Vasse M., Protais P. Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents. A potential role for an increased stimulation of D-1 dopamine receptors Neuropharmacology. 28:1989;931-939.
34. Vasse P., Protais P., Costentin J., Schwartz J.C. Unexpected potentiation by discriminant benzamide derivatives of stereotyped behaviours elicited by dopamine agonists in mice. Naunyn Schmiedebergs Arch. Pharmacol. 329:1985;107-114.
35. Zetler G. Neuroleptic-like, anticonvulsant and antinociceptive effects of aporphine alkaloids. Bulbocapnine, corytuberine, boldine and glaucine Arch. Int. Pharmacodyn. 296:1988;255-281.